Olic fuji pharma owner. As of today, Mitsui & Co.

Olic fuji pharma owner 5% YoY due to an increase in new CMO contracts Profit Attributable to Owners of Parent 2,432 2,432 2,696 264 10. 166 Moo 16, Bangpa-In Industrial Estate, Udomsorayuth Road, Bangkrason; Bangpa-In, Ayutthaya 13160; OLIC (Thailand) was OLIC （ t ） l IOPAMIDOL 136 IOHEXOL 7 Oral contraceptives +241 DIENOGEST +234 UTROGESTAN®+92 LEVONORGESTREL +44 LUNABELL® 62 Filgrastim +115 LIMAPROST ALFADEX 14 +654 141 +68 ±0 83 141 1,735 2,686 e e e Un-ID-19 e e e e e *2) OLIC : Our subsidiary CMO company (Head office and plant in Thailand) 6 Non-consolidated +1,163 OLIC 71 Fuji Pharma acquired OLIC (Thailand) Limited (hereafter, OLIC). (Fuji), for marketing Nextstellis (drospirenone and estetrol tablets) in Vietnam and Philippines. Conclusion of License and Supply Agreement of FSN-013 in Two ASEAN Countries (Vietnam and Philippines) Thailand, OLIC has expanded its business from a pure CMO company to a new hybrid company with CMO and pharmaceutical business with its own brand products. 4% 7. Agenda Chapter 1 Summary of FY9/23 2Q Consolidated Financial Results Chapter 2 Progress of Mid-Term Business Plan OLIC: Our subsidiary. OLIC Profit Attributable to Owners of Parent 2,641 2,641 2,642 1 0. 2019 For IR inquiries, please contact: Corporate Planning Division, Head Offi ce 6th Floor, Seitoh Kaikan, 5-7 Sambancho, Chiyoda-ku, Tokyo 102-0075 Japan OLIC (Thailand) Limited commissioned by Fuji Pharma to produce an external ointment medication 2018 Fuji Pharma partnership agreement concluded with Alvotech hf. 1997. Employee. We aim to generate pharmaceutical and other health care products of magnificent quality for society, serving both the domestic and Profit Attributable to Owners of Parent 2,432 2,432 2,696 264 10. Fuji Pharma is a specialty pharmaceutical company dealing with new drugs, biosimilars and generic drugs mainly in the fields of women’s healthcare and acute medical care. owns 6,875,000 stocks of Fuji Pharma (the ratio against the total number of outstanding shares as of September 30, CMO Business (OLIC)（exc. We offer comprehensive manufacturing services for pharmaceuticals, medical devices, cosmetics, food supplements, and veterinary products covering various dosage forms and packaging with state-of-the-art technology and Singapore: Japanese firm Fuji Pharma has entered into a share purchase agreement with swiss trading firm DKSH to acquire the shares of Olic (Thailand), the largest pharmaceutical contract manufacturer in Thailand. FY9/24 2Q Consolidated Financial Results. OLIC, a subsidiary in Thailand, reported a YoY increase in revenue due to new contracts and other factors. FY9/2024 2Q Investor Meeting Materials TSE Prime 4554. Although performance was better than we had forecast, a decrease in sales during the period was recorded. 7% 492 63. OK Cancel. 9% 2,562 105. Manufacturing Providing a broad spectrum of manufacturing offerings through differentiated technology and highly-customised processes. 1% YoY due to an increase in new contracts ⚫ Profit attributable to owners of parent： 187 JPY million ( 9. OLIC Meeting for Fuji Pharma Co. ("Fuji") announced that Fuji and our Thai subsidiary, OLIC (Thailand) Limited will become event partners of the Women's Health Innovation Summit ASIA (the "Event"), to be held in Singapore from March 22 to 23. 2527 (1984), OLIC (Thailand) Limited has been conducting our business with a passionate intent to promote healthy living. Moderator: Mr. TSE Prime. the Fuji Pharma Group 1,568 Thailand OLIC (Thailand) Limited 749 13 ingredients, 19 products Non-ionic contrast media for urography and angiography IOPAMIDOL injection F 1996 Contrast media *Aggregated by Fuji Pharma based on external data (as of March 2023) (diagnostic drugs) Oral bowel-cleansing agent SULPREP combination FY9/2020 Investor Meeting Materials Nov 20, 2020 Fuji Pharma Co. (TOKYO: 4519) and Fuji Pharma Co. 5 million on August 3, 2012. The approval will enable OLIC to make NEXTSTELLIS™ available to women across Thailand by the end of 2023. Takayuki Iwai, President & Chief Executive Officer of Fuji, commented: “This is an exciting opportunity and a significant global step for Fuji pharma group. This is the detailed information of the members of Japan CMO association. (hereinafter “Fuji Pharma”) announces that the Board of Directors Meeting held today decided on the following change of Representative Director and changes of officers. 68 billion baht). 6% - (OLIC) is the amount after consolidation adjustment (\million) * Underlined products are the Fuji Pharma branded drugs (branded drugs・branded generic drugs (transferred products) and biosimilars) Product by OLIC in Thailand. 46,138. Visit the News & Events section for the latest updates made available by OLIC Thailand. Agenda 2 Chapter 1 Business environment of focus field Chapter 2 FY9/24 2Q Consolidated Financial Results • OLIC S&M launches (launch of Nextstellis™ in Thailand and promotion of Fuji Pharma Co. (Tokyo Stock Exchange:4554, “Fuji”) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA, “Mithra”) today are pleased to announce that OLIC (Thailand) Limited (“OLIC”), a subsidiary of Fuji, has obtained the approval of import license for NEXTSTELLIS™, a novel combination [] Fuji Pharma Co. 2018 2020 OLIC transformed into a Contract Development and Innovation Fuji Pharma · Specialties: M&A Advisory · ประสบการณ์: OLIC (Thailand) Limited · สถานที่ตั้ง Fuji Pharma Co. The OLIC manufacturing facility complies with GMP requirements following the PIC/S guide to Good Manufacturing Practice for Medicinal Products. After the acquisition, Fuji Pharma invested substantially to upgrade the infrastructure and built a new state of the art parenteral facility. Corporate Office. Sustainability. 3B0qV1_usPGPLxzs96J-1UjTobsi-m5yRT69pLpUZoE. in Fuji Pharma. Building its presence outside Japan is one of the key OLIC: Sales up 34. Chapter 1. 24 October 2022 – 7:30 CET – Tokyo, Japan and Liege, Belgium – Fuji Pharma Co. com Email (Recruitment): recruitment. Summary of 2Q FY9/20 Consolidated Financial Results Profit Attributable to Owners of Parent 1,695 310 , -81. • OLIC S&M launches (launch of Nextstellis™ in Thailand and promotion of SEA expansion) Fuji Pharma Co. We have been a preferred partner for over 30 world-leading pharmaceutical companies and have manufactured over 600 different products. Contract manufacturing organizations (CMO) joined together and undertake research aimed at promoting the further growth and expansion of Japan’s CMO industry and resolving issues facing the industry, also work for the appropriate contract manufacturing with pharmaceutical companies. Business environment of focus field. 2% 6. a group company. 8% 2,562 43. Fuji Pharma is a renowned Japanese pharmaceutical firm. Investor Relations. tnloZ22h94bKV0SrttVPsj-B99NwrFY-ckTWlPETJdjoK14UZ4T3p-VIfw The acquisition is a significant step towards Fuji Pharma's aim to grow overseas and establish a new competitive edge as a pharmaceutical company. Of Total Sales YoY Change FY9/20 Fuji Pharma believes that building a stronger relationship with Mitsui & Co. A CMO company that Fuji Pharma Co. Therefore, we could facilitate As of today, Mitsui & Co. A CMO company that Fuji Pharma,Japan. 7 % FY2017 FY2018 FY2019 FY2020 Profit Attributable to Owners of Parent 2,432 2,432 2,696 264 10. Corporate Backed or Acquired. We offer a wide variety of contract manufacturing services from solids and injections to ・Fuji Pharma Co. 3% 6. OLIC (Thailand) Limited, we are one of the largest toll and contract manufacturers in Southeast Asia for branded pharmaceutical and healthcare Japan's Fuji Pharma has bought Thailand's largest pharmaceutical contract manufacturing organisation OLIC from current owner DKSH. financial results briefing for the second quarter of the fiscal year ending September 30, 2022. Takayuki Iwai, President and CEO. 30AM to 4. (Headquarter: Tokyo, Japan, President & CEO: Takayuki Iwai “Fuji”) announced today that OLIC (Thailand) Limited (Headquarter: Ayutthaya, Thailand “OLIC”) which is a subsidiary of Fuji has applied and accepted the submission for the import license of FSN-013, a novel combination drug Thank you for joining us today for the Fuji Pharma Co. E. Mr. A CMO company that owns a Thai headquarters and plant *1) Change in brand name: Iopamidol (old name: Oypalomine ®Note), Iohexol (old name: Iopark ®Note) 2,712 1,824 ts s s s n nd s t s n nts ts Non-consolidated 1,164 OLIC +335 55 59 199 400 60 216 235 +336 1 Rising API costs Increase in disposal “OLIC”; together with Fuji Pharma, collectively referred to as the “Group”). Of Total The acquisition is a significant step towards Fuji Pharma’s aim to grow overseas. Fuji 166 Moo 16, Bangpa-In Industrial Estate, Udomsorayuth Road, Bangkrason, Bangpa-In, Ayutthaya Province 13160, Thailand Mitrtown Office Tower, 16th Floor, 944 Rama IV Rd, Wangmai, Pathumwan, Bangkok 10330, Thailand contactus@olic-thailand. Head Office. Published: August 13, 2012 Fuji Pharma Co. Chapter 2. 10,712 30. 72 b253d08dc39b32e63ed2fe1425bd1. established 1965 1973 Fuji Pharma factory and research building built in Toyama as its principal manufacturing and research base Fuji Pharma medical drugs released for women 1974 Shares of Fuji Pharma registered for over-the-counter trading by the Japan Securities Dealers Association 1995 1996 Fuji Pharma contrast media Fuji Pharma Co. News . 2% 7. OLIC became the largest pharmaceutical contract manufacturer in Thailand in October 2012. 2. 3% 1,211 151. OLIC - Milestone. Working with this partner is expected to allow using OLIC to grow outside Foreign operation (OLIC) 2,866 3,467. Corporate Profile; Top Message; Corporate Philosophy; Mid-term Business Plan; Financial Highlights; Fuji Pharma Co. Fuji Pharma focuses on medical care for women, In Vitro diagnostics, acute medical care products and curative medicine (injection agents). 6% - - 7. 9% 5. Since then, we have been further strengthening Fuji Pharma. 4 billion ROE 6. 9% 31,680 34,229 35,387 37,909 36,279 1,630 -4. 6% (OLIC) 657 609 643 600 736 136 22. 2% Profit Margin 7. 746 21. Exhibition at CPhI South East Asia 2019 OLIC (Thailand) Limited (hereinafter “OLIC”), which is our subsidiary in Thailand, will exhibit at the international pharmaceutical exhibition, CPhI South East Asia 2019 in Queen Sirikit National Convention Center (QSNCC), Bangkok, Thailand. 6% - (OLIC) is the amount after consolidation adjustment (\million) * Underlined products are the Fuji Pharma branded drugs (branded drugs・branded generic drugs (transferred products) and biosimilars) Contents Introduction 1 Corporate Philosophies 3 Health Issues Surrounding Women 5 At a Glance 7 Our Journey to Date and Cultivated Strength Value Creation Story 9 Fuji Pharma’s Value Creation Process 11 Message from the President 15 Vision for 2030 and Mid-Term Business Plan 16 Progress of Mid-Term Business Plan 21 Financial Report 22 Strengthening OLIC (Thailand) Limited OLIC (Thailand) Limited (hereinafter “OLIC”), subsidiary of Fuji Pharma Co. ("Fuji") announced that Fuji’s Thai subsidiary, OLIC (Thailand) Limited (“OLIC”) held a commemorative symposium titled "Take-off The 1st NE4ST with DRSP to the next era" ("the Symposium") on April 27 in Bangkok, on the occasion of the launch of "Nextstellis™". 9%, well below the medium-term target of The acquisition is a significant step towards Fuji Pharma’s aim to grow overseas. Explore our Fuji Pharma group policy to learn more about our commitment to a sustainable future. OLIC wishes that all Thai people will have good health and long life. Of Total Fuji Pharma Co. o@olic-thailand. Discover how our experts ensure you’re getting the most accurate financial data in the industry. Nextstellis is a novel combination medication comprising of drospirenone (DRSP) and estetrol (E4), indicated for use by women of reproductive age to prevent Fuji Pharma Co. com Phone +66 35 221 031 up to 6 (Office) Fax +66 35 221 030 Operating Hours: 7. FY9/2024 2Q Investor Meeting Materials. 9% Total 27,872 27,324 24,899 25,498 26,470 972 3. 5 Japan's Fuji Pharma has bought Thailand's largest pharmaceutical contract manufacturing organisation OLIC from current owner DKSH. First of all, I would like to introduce today's attendees. 2% YoY, driven by contributions from new products, acquired products, and existing women’s healthcare products Profit: Up 12. : 902 ・OLIC (Thailand) Limited: 756 Thank you for visiting the FujiPharma website. OLIC moved to new base in Bangpa-in Industrial Estate, Ayutthaya,Thailand. TOKYO, September 1, 2016 -- Chugai Pharmaceutical Co. (hereinafter ”FUJI”), are pleased to announce that OLIC has built a new injection facility and a warehouse (hereinafter “New Facilities”) inside premises of OLIC and held an inauguration ceremony on January 19th 2017. , Ltd. Fuji Pharma will acquire 0. The new Japanese owner has significant manufacturing expertise and is committed to growing overseas and establishing a new competitive edge as a pharmaceutical company. OLIC is significantly higher than the forecast, but this is due to temporary income based on the provisions of the consignment contract. TSE1 4554 existing women's healthcare products and OLIC Sales: Up 4. * Underlined products are the Fuji Pharma branded drugs (branded drugs, branded generic drugs (transferred products) and biosimilars) * CMO Business (OLIC) is the amount after consolidation adjustment FY9/23 Total Total Top 15 Sales Pct. 3% YoY) –Sold cross-shareholdings in the previous fiscal Fuji Pharma Co. A member of Fuji Pharma Group Moving Together with Trust. by supply outstanding pharmaceutical and healthcare products. 0% 2,562 103. 8% YoY due to SG&A expenses saving OLIC: Sales up 34. genda. com OLIC is the largest provider of contract manufacturing services in Southeast Asia for pharmaceutical, healthcare and personal care products. 8% ※CMO Business (OLIC) is the amount after consolidation adjustment * Underlined products are the Fuji Pharma branded drugs (branded drugs, branded generic drugs Additionally, OLIC focuses on providing women's healthcare products that correspond with Fuji Pharma's long-term visions of becoming a pharmaceutical partnership for women's health, as well as enhancing access to medications in ASEAN. (TOKYO: 4554) announced today that they agreed to transfer the rights to manufacture and market VESANOID ® (generic name: tretinoin, brand name: VESANOID ® capsule 10mg) in Japan for the indication of acute promyelocytic leukemia (APL), from Chugai to Fuji Pharma Championing the well-being of people particularly women in Asia, Japanese developer and marketer of pharmaceutical products Fuji Pharma is expanding its borders to serve markets in Asia and beyond. Profit Attributable to Owners of Parent 2,021 2,021 1,834 187 -9. 91% stake in Olic Limited from DKSH Holding Ltd. OLIC was founded in 1984 and became a member of the Fuji Pharma Fuji Pharma Co. 743 (asof Sep2021) OLIC - Company Overview. 5% 35,426 40,889. OLIC （ t ） l IOPAMIDOL 136 IOHEXOL 7 Oral contraceptives +241 DIENOGEST +234 UTROGESTAN®+92 LEVONORGESTREL +44 LUNABELL® 62 Filgrastim +115 LIMAPROST ALFADEX 14 +654 141 +68 ±0 83 141 1,735 2,686 e e e Un-ID-19 e e e e e *2) OLIC : Our subsidiary CMO company (Head office and plant in Thailand) 6 Non-consolidated +1,163 OLIC 71 *2) OLIC: Our subsidiary. 6% ※CMO Business (OLIC) is the amount after consolidation adjustment * Underlined products are the Fuji Pharma branded drugs (branded drugs・branded generic drugs Fuji Pharma Co. 2% YoY, driven by contributions from new products, Profit Attributable to Owners of Parent 2,432 2,432 2,696 264 10. The share purchase agreement was approved by the board of directors of Fuji Pharma on August 3, 2012. Fuji Pharma and OLIC support Women's Health Innovation Summit ASIA as event partners Fuji Pharma Co. Awards & Certificates. Fuji Pharma is mainly engaged in the manufacture and sale of medical products – hormone medicines for the obstetrics and gynaecology department, as OLIC (Thailand) Limited | 937 followers on LinkedIn. The products manufactured by OLIC are not only distributed in Thailand, but across Asia and the rest of the world, and since 2000, Fuji Pharma has also contracted some of its products to OLIC. Additionally, OLIC focuses on providing women's healthcare products that correspond with Fuji Pharma's long-term visions of becoming a pharmaceutical partnership for women's health, as well as enhancing access to medications in The Approval to sell in Japan IOPAQUE® injection manufactured by OLIC (Thailand) will improve Fuji Pharma’s ability to supply its key products with consistency. Intra-group transactions） 2,231 2,281 2,464 2,636 2,870 234 8. Atsuya Mitsuhashi, Executive Corporate Officer. We aim to generate pharmaceutical and other health care products of magnificent quality for society, serving both the domestic and Ownership Status. 1% ROA 4. 6% (OLIC) FY9/22 First Half Sales JPY 17,726 million FY9/18 First half FY9/19 First half FY9/20 First half FY9/21 * Underlined products are the Fuji Pharma branded drugs (branded drugs, branded generic drugs (transferred products) and biosimilars) Profit Attributable to Owners of Parent 1,328 1,328 1,118 210 -15. The company invests in the development, manufacturing and marketing of pharmaceutical products, such as injection agents, drugs for internal and external use, and diagnostic products. 7% OLIC : Our subsidiary CMO company (Head office and plant in Thailand) *1) Product name change：IOPAMIDOL injection（Former name：2<3$/20,1 OLIC: Sales up 34. A. According to Fuji Pharma, the purchase price of the Olic business is worth approximately $53 million (1. OLIC’s managing director, Toyoyuki Kamide, talks about the company's new manufacturing facility, its merger with Fuji Pharma, and its status as the number one contract OLIC was founded in 1984 and became a member of the Fuji Pharma Group, a Tokyo-based Japanese pharmaceutical company in 2012. Fuji focuses on the field of women’s health care with a wide variety of new and generic drugs for women’s specific diseases such as infertility, dysmenorrhea Fuji Pharma is a renowned Japanese pharmaceutical firm. 4554. of Fuji PharmaCo. 0% * CMO Business (OLIC) is the amount after consolidation adjustment Total Top 15 Sales Pct. entered into a share purchase agreement to acquire 99. 's Second Quarter of the Fiscal Year ending September 30, 2023. 3% Acute Medical Care ＊Underlined products are the Fuji Pharma branded drugs, (branded drugs・branded generic drugs (transferred products) and biosimilars) Total Women’s Healthcare FY9/17 FY9/ 19 YoY 18 Additionally, OLIC focuses on providing women's healthcare products that correspond with Fuji Pharma's long-term visions of becoming a pharmaceutical partnership for women's health, as well as enhancing access to medications in ASEAN. Explore Our Group existing women's healthcare products and OLIC Sales: Up 4. In the age of innovation and development, OLIC transform to a prosperous future, represented by the new company identity and logo, with the slogan "Moving Together with Trust". 2% Acute Medical Care Women's Healthcare * Underlined products are the Fuji Pharma branded drugs (branded drugs・branded generic drugs (transferred products) and biosimilars) * Foreign operation (OLIC) is the amount after consolidation adjustment YoY Pct OLIC has cultivated successful relationships that last. In a deal that marks its first major Fuji Pharma Co Ltd announced on 3 August 2012 that it has entered into an agreement to acquire the shares of OLIC (Thailand) Ltd, the largest pharmaceutical contract manufacturer in What is Fuji Pharma’s role within OLIC (Thailand) Limited? Fuji Pharma’s relationship with OLIC began in 2000 when OLIC began contract manufacturing products for Fuji Pharma being sold in Japan. ,Ltd. Published: August 13, 2012 OLIC has exported pharmaceutical products outside Thailand and Japan for many years, compliant to the GMP standards of each country. As a result, ROE declined 2 percentage points year-on-year to 7. 15PM Warehouse Working Hours: Monday – Fuji is a Tokyo Stock Exchange (TSE) listed, Japan‐based pharmaceutical company mainly engaged in the manufacture and sale of prescription-based pharmaceutical products. , which has an extensive global network, will help make the operations of Fuji Pharma and OLIC (the “Fuji Pharma Group” hereafter) even more powerful. Iwai: Thank you. 2012 2017 CHIYO, a new state of parenteral facility in OLIC：Net sales +22. Crick “OK” to continue. OLIC was Meet OLIC (Thailand) a member of Fuji Pharma Group Booth J02 at CPHI South East Asia 2024 10-12 July 2024 10:00-18:00 pm. In a deal that marks its first major expansion into overseas production, the transaction has been valued at around $53 million and it is expected to close in October. QSNCC ขอขอบคุณ [Company Name] Fuji Pharma Co. (Tokyo Stock Exchange:4554, “Fuji”) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA, “Mithra”) today are pleased to announce that OLIC (Thailand) Limited (“OLIC”), a subsidiary of Fuji, has obtained the approval of import license for NEXTSTELLIS™, a novel combination contraceptive containing estetrol and drospirenone Manufacturing Providing a broad spectrum of manufacturing offerings through differentiated technology and highly-customised processes. Because Quality & Expertise are not built in one day 1984 1997 OLIC commissioned a new plant in Bangpa-In Industrial Estate, Ayutthaya, Thailand. We offer comprehensive manufacturing services for pharmaceuticals, medical devices, cosmetics, food supplements, and veterinary products covering various dosage forms and packaging with state-of-the-art technology and Fuji Pharma Co. OLIC (Thailand) Limited commissioned by Fuji Pharma to manufacture an external use drug (ointment) 2004 Fuji Pharma is a specialty pharmaceutical company dealing with new owners of parent JPY 2. 1% - * Underlined products are the Fuji Pharma branded drugs (branded drugs・branded generic drugs (transferred products) and biosimilars) Fuji Pharma. Since B. ≪Overview≫ Fuji Pharma is a renowned Japanese pharmaceutical firm. Acquired/Merged (Operating Subsidiary) Financing Status. Business Results for the Fiscal Year Ended September 30, 2020 November 20, 2020. 6% * Underlined products are the Fuji Pharma branded drugs (branded drugs・branded generic drugs (transferred products Contents Introduction 1 Corporate Philosophies 3 Health Issues Surrounding Women 5 At a Glance 7 Our Journey to Date and Cultivated Strength Value Creation Story 9 Fuji Pharma’s Value Creation Process 11 Message from the President 15 Vision for 2030 and Mid-Term Business Plan 16 Progress of Mid-Term Business Plan 21 Financial Report 22 Strengthening Fuji Pharma Co. 5% YoY due to an increase in new CMO contracts ⚫ R&D Related Topics F-meno®Capsules: Launched * Underlined products are the Fuji Pharma branded drugs (branded drugs, branded generic drugs (transferred products) and biosimilars) * CMO Business (OLIC) is the amount after consolidation adjustment FY9/23 Total Total Top 15 Sales Pct. We operate with modern production technologies to achieve our goal of creating a society with sustainable health, where everyone lives happily and healthily. Published: August 13, 2012 OLIC positions ourself as more than a pharmaceutical manufacturer. FY9/2021 Investor Meeting Materials TSE1 4554 Profit Attributable to Owners of Parent 2,085 2,432 347 16. 1% (OLIC) 1,925 1,887 1,896 1,565 2,174 609 38. Chapter 3. 7% Total 9,957 10,279 8,968 9,295 9,446 151 1. recorded at the Toyama Plant following the transfer of the manufacturing of contrast media to OLIC. 1% - * Underlined products are the Fuji Pharma branded drugs (branded drugs・branded generic drugs (transferred products) and biosimilars) DKSH Divests Contract Manufacturing Plant OLIC to Fuji Pharma. First of all, let me begin by introducing today's speakers. The acquisition is a significant step towards Fuji Pharma's DKSH, the leading Swiss trading firm, decided to sell its Olic pharmaceutical manufacturing plant in Ayutthaya province to Japanese pharmaceutical firm Fuji Pharma. 4,213. FY9/2023 2Q Investor Meeting Materials TSE Prime 4554. OLIC became. After which, Fuji Pharma Co. 4% 2,562 71. The company is a trusted partner to over 30 multinational companies, including most of the Big Pharma organizations. CSR. Bangpa-in Industrial Estate, Ayutthaya, Thailand. Our data operations team has logged over 3. [Company ID] 4554-QCODE [Event Language] JPN [Event Type] Earnings Announcement [Event Name] FY9/2021 Investor Meeting OLIC suffered from a decline in orders due to COVID-19 impact. 2012 2017 OLIC became a subsidiary of Fuji Pharma Co. Of Total OLIC （ t ） l IOPAMIDOL 136 IOHEXOL 7 Oral contraceptives +241 DIENOGEST +234 UTROGESTAN®+92 LEVONORGESTREL +44 LUNABELL® 62 Filgrastim +115 LIMAPROST ALFADEX 14 +654 141 +68 ±0 83 141 1,735 2,686 e e e Un-ID-19 e e e e e *2) OLIC : Our subsidiary CMO company (Head office and plant in Thailand) 6 Non-consolidated +1,163 OLIC 71 OLIC (Thailand) Limited is the largest provider of contract manufacturing services for pharmaceutical, healthcare, confectionary and supplement industries in Thailand and South-East Asia. FY9/2022 2Q Investor Meeting Materials Fuji Pharma Co. DKSH Divests Contract Manufacturing Plant OLIC to Fuji Pharma. (“Fuji Pharma”) today announced that it has entered into a share purchase agreement (“Share Purchase Agreement”) to acquire the shares of OLIC (Thailand) OLIC (Thailand) was acquired by Fuji Pharma. With this conclusion of this agreement, Fuji (OLIC), a subsidiary of the renowned Japanese pharmaceutical company Fuji Pharma Co. Fuji Pharma Co. The company invests in the development, manufacturing and marketing of pharmaceutical products, such as injection agents, drugs for internal and external use, and diagnostic Fuji Pharma Co. You are now moving to an external website. €Olic,. for CHF 52. Fuji Pharma also believes this Approval will contribute to its growth. In terms of operating income, gross profit decreased due to the coronavirus pandemic, and R&D expenses Head Office 166 Moo 16, Bangpa-In Industrial Estate, Udomsorayuth Road, Bangkrason, Bangpa-In, Ayutthaya Province 13160, Thailand Email (General Inquiry): contactus@olic-thailand. In addition, OLIC (Thailand) plans to manufacture pharmaceuticals for sale in Thailand and other Southeast DKSH Divests Contract Manufacturing Plant OLIC to Fuji Pharma. 6% 2,100 332 Profit Margin 6. Financial Results Briefing for the Fiscal Year Ended September 2019 November 19, 2019. It will gain access to OLIC’s factory, manufacturing know-how and its customer base [1]. History & Heritage About OLIC. 2% ROE 5. nexv xab ltu kqboo rllah tjythldb ffefyc hoormk ddgaxkgg hcytvj